{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-220722","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2025-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.588856+00:00","generated_at":"2026-05-17T05:34:12.624339+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Quince amends EIB credit facility; min cash balance reduced to EUR 5M for Q1 2026","bullets":["Minimum cash balance reduced from EUR 14.65M to EUR 5M for Jan-Mar 2026 period.","1% of 9% deferred interest converted to fixed rate, payable March 31, 2026.","Amendment dated September 25, 2025 under EIB Facility originally July 24, 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-220722","json":"https://secwatch.observer/filing/0001193125-25-220722.json","markdown":"https://secwatch.observer/filing/0001193125-25-220722.md","text":"https://secwatch.observer/filing/0001193125-25-220722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312525220722/0001193125-25-220722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312525220722/d911581d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:34:12.624339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}